Seeking Alpha

Renaissance Cap...'s  Instablog

Renaissance Capital IPO Research
  • on IPO Analysis
Send Message
Renaissance Capital’s research analysts provide unbiased and comprehensive coverage of the U.S. and international IPO markets. Through Renaissance Capital’s research service, clients get a hard-nosed, independent opinion, in-depth fundamental analysis and customizable financial models on all... More
My company:
Renaissance Capital LLC
My blog:
IPO News from Renaissance Capital
My book:
IPOs for Everyone
  • Last week sees eight companies file for IPOs 0 comments
    Nov 23, 2009 12:06 PM
    Eight companies filed with the SEC to go public last week, three of which were Chinese companies planning to offer American Depository Shares.

    The week started off with Hirschfeld Industries (HSFD), a leading integrated provider of highly-engineered steel components for infrastructure applications, which filed on Monday to raise up to $150 million in its initial public offering. The San Angelo, TX-based company, which was founded in 1946 and booked $321 million in sales over the last 12 months, plans to list on the NYSE under the symbol HSFD. J.P. Morgan and Robert Baird are the lead underwriters on the deal.

    Concord Medical Services (CCM) followed, filing on Tuesday to raise up to $100 million. The leading operator of radiotherapy and diagnostic imaging centers in China was founded in 2007 and booked $36 million in sales over the last 12 months. The Beijing-based company plans to list on the NYSE with Morgan Stanley, J.P. Morgan, and CICC acting as the lead underwriters on the deal.

    On Wednesday, Linkage Technologies International Holdings (BOSS), a leading provider of software solutions and IT services for the telecommunications industry in China, filed to raise up to $175 million in its IPO. The Nanjing-based company, which commenced operations in 1997 and booked $122 million in sales over the last 12 months, plans to list on the NYSE. Proceeds from the deal will be used for research and development efforts, as well as general corporate purposes. Citi and Barclays Capital are the lead underwriters on the deal.

    Online marketing company QuinStreet (QNST), which delivers measurable traffic results to clients in information-intensive industry verticals, filed on Thursday with the SEC to raise up to $250 million. The Foster City, CA-based company, which was founded in 1999 and booked $275 million in sales over the last 12 months, plans to list under the symbol QNST with Credit Suisse, BofA Merrill Lynch, and J.P. Morgan acting as the lead underwriters on the deal.

    Rounding out the week were Calix Networks, Fabrinet, Ironwood Pharmaceuticals, and China Nuokang Bio-Pharmaceutical, all of which submitted their filings on Friday.

    Calix Networks (CALX), which provides communications access systems and software that allow service providers (CSPs) to connect to their residential and business subscribers, was founded in 1999 and booked $215 million in sales over the last 12 months. The company plans to list on the NYSE under the symbol CALX and raise up to $100 million. Goldman Sachs, Morgan Stanley, and Jefferies are the lead underwriters on the deal.

    Fabrinet (FN) provides foundry services to OEMs and sells application-specific bulk optical materials and filed to raise up to $150 million. The company was founded in 2000 and booked $392 million in sales over the last 12 months and plans to list on the NYSE under the symbol FN. Morgan Stanley and Deutsche Bank are the lead underwriters on the deal. Fabrinet had previously filed for a $250 million IPO earlier this year, but pulled the deal due to unfavorable market conditions.

    Ironwood Pharmaceuticals (IRWD), which discovers, develops and intends to commercialize innovative medicines targeting therapeutic needs, filed to raise up to $173 million. The Boston-based company, which was founded in 1998 and booked $32 million in sales over the last 12 months, plans to list on the NASDAQ under the symbol IRWD with J.P. Morgan, Morgan Stanley and Credit Suisse acting as the lead underwriters on the deal.

    In a smaller deal, China Nuokang Bio-Pharmaceutical (NKBP), plans to offer 5 million ADSs, including 473,000 from selling shareholders, at a price between $10 and $12 per ADS. The company sells 14 hematological and cardiovascular pharmaceutical products and will use Jefferies as the sole underwriter on the deal. The stock is expected to list on the NASDAQ.
Back To Renaissance Capital IPO Research's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

StockTalks

More »
Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.